Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I
Department of Surgery II, School of Medicine, Kanazawa University, Ishikawa, Japan.
Cancer. 1992 Dec 15;70(12):2778-84. doi: 10.1002/1097-0142(19921215)70:12<2778::aid-cncr2820701209>3.0.co;2-l.
The expression of p53 protein in 100 large bowel cancers was studied immunohistochemically by use of a monoclonal antibody (PAb1801).
Immunoreactivity was found in 61.0% of specimens from 100 patients with colorectal cancer. The pattern of p53 expression was mainly detected in the nuclei of the cancer cells. There was no significant correlation between the expression of p53 and the histologic grade, tumor size, serosal invasion, lymphatic invasion, venous invasion, lymph node metastasis, or liver metastasis. However, patients with p53-positive tumors had a greater relative risk of death compared with those with p53-negative tumors. The p53 negative-tumors showed a recurrence rate of 5.9%; for the p53 positive-tumors, a recurrence rate of 23.8% was recorded. The 3-year survival rate was 96.7% of 39 patients with p53-negative carcinomas and 61.8% for the patients with p53-positive tumors; there was a significant difference in the rate between the two groups of patients (P < 0.05). The growth fraction of p53-positive tumors determined with a monoclonal antibody against DNA polymerase alpha (49.0%) was significantly higher than that of p53-negative tumors (40.7%, P < 0.01).
These results suggest that the immunoreactivity of p53 may be a biologic marker of prognostic significance.
采用单克隆抗体（PAb1801）免疫组织化学方法研究了100例大肠癌中p53蛋白的表达情况。
100例结直肠癌患者的标本中，61.0%呈现免疫反应性。p53表达模式主要在癌细胞核中检测到。p53的表达与组织学分级、肿瘤大小、浆膜侵犯、淋巴侵犯、静脉侵犯、淋巴结转移或肝转移之间无显著相关性。然而，与p53阴性肿瘤患者相比，p53阳性肿瘤患者的相对死亡风险更高。p53阴性肿瘤的复发率为5.9%；p53阳性肿瘤的复发率为23.8%。39例p53阴性癌患者的3年生存率为96.7%，p53阳性肿瘤患者的3年生存率为61.8%；两组患者的生存率之间存在显著差异（P < 0.05）。用抗DNA聚合酶α单克隆抗体测定的p53阳性肿瘤的生长分数（49.0%）显著高于p53阴性肿瘤（40.7%，P < 0.01）。
这些结果表明，p53的免疫反应性可能是具有预后意义的生物学标志物。
